bannerhome
 
 

ABOUT

Our Mission

Transform treatment by harnessing the power of T cells to create a new generation of targeted cancer immunotherapies and infectious disease vaccines.

About PDS Biotech

PDS Biotech was established with the goal of harnessing the power of T cells to address some of the most devastating illnesses of our time. While many companies have tried to leverage the body’s own immune system to induce a powerful T cell response, most have been unsuccessful in inducing the right type and quantity of potent tumor-infiltrating T cells to execute a targeted attack. Scientists at PDS Biotech designed proprietary cationic, lipid-based nanoparticle platform technologies to overcome these limitations.

When paired with proprietary tumor-associated proteins called antigens, Versamune® has been shown to promote the induction of the right type and quantity of potent tumor-infiltrating killer and helper T cells, that specifically recognize the tumor antigen. PDS0301, our novel tumor-targeting IL-12 immunotherapy, when used with Versamune® overcomes tumor-induced suppression of the immune system. The proprietary combination also promotes enhanced infiltration and expansion of the T cells within the tumor leading to more effective immunotherapy. Our Infectimune™ platform is being used in the development of novel T cell and antibody inducing preventive vaccines.

PDS Biotech is committed to developing novel immunotherapies based on our T cell activating platforms to save and improve the lives of patients worldwide:

  • Versamune® based immunotherapies to provide a targeted T cell attack against tumor-associated proteins called antigens
  • Versamune® based immunotherapy plus PDS0301, our novel tumor-targeting IL-12 immunotherapy, promotes enhanced infiltration and expansion of the T cells within the tumor to treat recurrent/metastatic cancers with poor survival prognosis
  • Infectimune™ based vaccines to provide robust and durable protection against selected deadly infectious diseases

Receive Email Alerts

Join our mailing list to receive the latest news and updates from our team.

Sign up

pdf